DOCSLIB.ORG

Osaka University Immunology Frontier Research Center

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Osaka University Immunology Frontier Research Center WPI WPI I mmunology mmunology F rontier rontier Re search search C enter FY 2013 enter WPI WPI I mmunology F rontier Re search World Premier International Research Center C enter Osaka University FY 2013 Immunology Frontier Research Center Annual Report of IFReC OsakaUniversity FY 2013 Copyright : Immunology Frontier Research Center (IFReC), Osaka University Edit : Research Planning & Management Oce, IFReC Published in June, 2014 World Premier International Research Center Message from the Director Osaka University Immunology As the Director of the Immunology Frontier As an approach to nurturing young research- Frontier Research Center (WPI-IFReC) at Osaka University, ers, the third NIF Winter School, which was I am very pleased to present the IFReC annual begun in 2011, was held in January, 2014 on Awaji Research report for scal 2013. Island. The young researchers, selected from a highly competitive eld of candidates, spent one Since its inception in 2007, IFReC has estab- week living and debating together in an Center lished itself as a Visible International Research ‘Immunology Boot Camp’ that is fast becoming Center of Immunology with the support of many an institution of its own. The school prides itself people including the WPI Program Committee, on oering not only productive educational the Program Director and the Program Ocers. content but also an opportunity for the young In the WPI interim evaluation carried out at the researchers to form a global network. end of scal year 2011, IFReC was awarded a We are committed to continuing contribu- score of ‘A’ and it was noted that IFReC should be tions to scientic advances through immunology made a permanent part of the University as an research and education and the evolvement of a International Level Research Institute. In align- Visible Research Center that leads the world. ment with this view, we are currently nalizing the future direction of IFReC at Osaka University with the University Executive Board as well as the Ministry of Education, Culture, Sports, Science and Technology (MEXT). We expect that an important decision will be made as to the Contents continuation of IFReC beyond 2017 at the WPI Message from the Director ................................................... 1 Science Talk Live 2013 by WPI ............................................. 83 program committee meeting to be held in fall Organization Chart .................................................................. 2 Symposium for General Audience ..................................... 84 2014. Committee and Advisory Board for IFReC ....................... 4 AAAS 2014 .................................................................................. 85 To this end, IFReC must also demonstrate its Administrative Oce of IFReC ............................................. 6 Research Projects ........................................................................ 87 worth as a World Premier Research Institute. Laboratories .................................................................................. 7 Research Support Program for However, it is not sucient to simply maintain Immunology Group ................................................................. 8 Fusion of Dierent Fields ...................................................... 88 the level of research. IFReC has been running an Imaging Group .......................................................................... 38 Combined Research Fields Evaluation Workshop ........ 90 original research grant ‘Research Support Informatics Group .................................................................... 52 Dual Mentor Program ............................................................. 91 Young Scientist Support Program for Research Abroad Program for Combined Research Fields’ in order Units for Combined Research Fields ................................. 56 FIRST Program : AKIRA Project ............................................. 92 to promote collaborative studies between dier- Symposia & Seminars ............................................................... 61 Data ................................................................................................... 97 ent elds. In 2013, two Combined Research Units International Symposium TCUID ........................................ 62 Facilities ....................................................................................... 98 were set up to advance this program. Both units Immunology Frontier "B to B Seminar" ............................ 64 Kishimoto Foundation Fellowships ................................... 100 comprise a group of young, talented researchers Mini Symposium on Malaria Immunopathology Members ..................................................................................... 101 from dierent elds and we expect that lively Kishimoto Foundation Lecture ........................................... 65 Awards ......................................................................................... 102 debate will pave the way to new areas of IFReC Seminars .......................................................................... 66 Finance ......................................................................................... 104 research. IFReC Colloquia ......................................................................... 68 Research Outputs ....................................................................... 105 Live Immuno-Imaging Facility Opening Workshop .... 70 Selected Articles ....................................................................... 106 Events ............................................................................................... 71 Publications ................................................................................ 110 Winter School ............................................................................ 72 Lectures by PIs ........................................................................... 116 Sta and Researchers Development Seminars ............. 74 Access Map ..................................................................................... 118 Japanese Lessons ..................................................................... 76 Outreach Activities .................................................................... 79 Science Café Series “Café on the Edge” ............................ 80 Shizuo Akira, MD/PhD Super Science High School Festa 2013 ............................ 81 Director WPI Immunology Frontier Science Agora 2013 ................................................................. 82 Research Center 1 Immunology Group Organization Chart Host Defense ......................................................................................Shizuo Akira Immunoglycobiology .....................................................................Taroh Kinoshita Immunopathology ..........................................................................Atsushi Kumanogoh Immunochemistry ............................................................................Hisashi Arase MEXT Immune Regulation .........................................................................Tadamitsu Kishimoto Mucosal Immunology .....................................................................Kiyoshi Takeda WPI Initiative Molecular Immunology .................................................................Hitoshi Kikutani Program Committee JSPS Experimental Immunology ...........................................................Shimon Sakaguchi Cell Signaling......................................................................................Takashi Saito WPI Working Group Lymphocyte Dierentiation .........................................................Tomohiro Kurosaki Lymphocyte Development ...........................................................Fritz Melchers Malaria Immunology .......................................................................Cevayir Coban Vaccine Science .................................................................................Ken J. Ishii Immune Regulation .........................................................................Tsuneyasu Kaisho International Immune Network .............................................................................Rikinari Hanayama Scientic Advisory Board Immunoparasitology ......................................................................Masahiro Yamamoto Imaging Group Single Molecule Imaging ...............................................................Toshio Yanagida Director Research Groups Biofunctional Imaging ....................................................................Yoshichika Yoshioka Immunology and Cell Biology .....................................................Masaru Ishii Nuclear Medicine .............................................................................Jun Hatazawa Management Biophotonics ......................................................................................Nicholas Isaac Smith Deputy Directors Committee Chemical Imaging Techniques ....................................................Kazuya Kikuchi Immune Response Dynamics ......................................................Kazuhiro Suzuki Board of Informatics Group Representatives Administrative Information Systems .......................................................................Yutaka Hata Director Systems Immunology .....................................................................Daron M. Standley General Aairs Section
Load more

Recommended publications
  • 2008 Keio Medical Science Prize Winner Announcement
    FOR IMMEDIATE RELEASE http://www.keio.ac.jp/ October 2, 2008 2008 Keio Medical Science Prize Winner Announcement Keio University presents the “Keio Medical Science Prize” to researchers in recognition of their outstanding achievements in the fields of medical or life sciences. It is the only prize of its kind to be awarded by a Japanese university. The 13th Keio Medical Science Prize will be awarded to Dr. Fred H. Gage and Dr. Shimon Sakaguchi. Fred H. Gage, Ph.D. Adler Professor, Laboratory of Genetics, The Salk Institute for Biological Studies, U.S.A. For the discovery of physiological roles of adult neurogenesis in mammalian brain Shimon Sakaguchi, M.D., Ph.D. Professor, Department of Experimental Pathology, Institute for Frontier Medical Sciences, Kyoto University, Japan For the discovery of regulatory T cells and their roles in immunological diseases Award Ceremony and Commemorative Symposium The award ceremony and a commemorative lecture given by the prize winners will be held on November 21, 2008 and a commemorative symposium will take place on November 22. Both events will be held at the Keio University School of Medicine (Shinanomachi Campus). Please contact below for any inquiries. (eg. interviews or photographs) Attachments : (1) About the Keio University Medical Science Fund (2)2008 Prize Winner: Fred H. Gage（Theme, CV, message） (3)2008 Prize Winner: Shimon Sakaguchi（Theme, CV, message） (4)2008 Keio Medical Science Prize Award Ceremony/Commemorative Lecture/ Commemorative Symposium Inquiries: Keio University Medical Science Fund（Ms. Masako Kawai, Ms. Akiko Murai） TEL: +81-3-5363-3609 URL: http://www.ms-fund.keio.ac.jp/prize/ FAX: +81-3-5363-3610 E-mail:[email protected] 1/5 Attachment About the Keio University Medical Science Fund Background In 1994, Dr.
    [Show full text]
  • Chemokine Receptors in Allergic Diseases Laure Castan, A
    Chemokine receptors in allergic diseases Laure Castan, A. Magnan, Grégory Bouchaud To cite this version: Laure Castan, A. Magnan, Grégory Bouchaud. Chemokine receptors in allergic diseases. Allergy, Wiley, 2017, 72 (5), pp.682-690. 10.1111/all.13089. hal-01602523 HAL Id: hal-01602523 https://hal.archives-ouvertes.fr/hal-01602523 Submitted on 11 Jul 2018 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. Distributed under a Creative Commons Attribution - ShareAlike| 4.0 International License Allergy REVIEW ARTICLE Chemokine receptors in allergic diseases L. Castan1,2,3,4, A. Magnan2,3,5 & G. Bouchaud1 1INRA, UR1268 BIA; 2INSERM, UMR1087, lnstitut du thorax; 3CNRS, UMR6291; 4Universite de Nantes; 5CHU de Nantes, Service de Pneumologie, Institut du thorax, Nantes, France To cite this article: Castan L, Magnan A, Bouchaud G. Chemokine receptors in allergic diseases. Allergy 2017; 72: 682–690. Keywords Abstract asthma; atopic dermatitis; chemokine; Under homeostatic conditions, as well as in various diseases, leukocyte migration chemokine receptor; food allergy. is a crucial issue for the immune system that is mainly organized through the acti- Correspondence vation of bone marrow-derived cells in various tissues. Immune cell trafficking is Gregory Bouchaud, INRA, UR1268 BIA, rue orchestrated by a family of small proteins called chemokines.
    [Show full text]
  • The John Curtin School of Medical Research Annual Review 2012
    THE JOHN CURTIN SCHOOL OF MEDICAL RESEARCH ANNUAL REVIEW 2012 ANU College of Medicine, Biology & Environment CONTENTS Annual Review 2012 From the Director 3 The John Curtin School of Medical Organisation Chart 4 Research Committees 5 COMMUNITY 7 Official Opening of Stage 3 8 Launch of The John Curtin Medical Research Foundation 9 Professor Gordon Ada 10 Open Day 11 Community Activities 12 RESEARCH IN REVIEW 2012 15 Eccles Institute of Neuroscience 16 Department of Genome Biology 29 Department of Immunology 36 Department of Pathogens and Immunity 45 Department of Molecular Bioscience 47 Department of Translational Medicine 56 Australian Phenomics Facility 60 Biomolecular Resource Facility/Genome Discovery Unit 61 STAFF AND STUDENT ACHIEVEMENTS 63 VISITORS AND COLLABORATIONS 69 STAFF AND STUDENTS 85 Department of Genome Biology 86 Department of Immunology 87 Eccles Institute of Neuroscience 88 Department of Pathogens and Immunity 90 Department of Molecular Bioscience 90 Department of Translational Medicine 92 APF and Animal Services 92 School Services 94 School Administration 95 Students 96 PUBLICATIONS, PRESENTATIONS AND COMMUNITY OUTREACH 99 SUPPORT 129 Grants 130 Financial Overview 134 Donors 135 Sponsors 136 Annual Review 2012 1 2 The John Curtin School of Medical Research FROM THE DIRECTOR Zinkernagel. He will be sadly missed by his many friends and colleagues at the School, who have established the annual Gordon Ada New Investigator Award in his memory. In 2012, we finally completed the long and very necessary redevelopment project that resulted in the new John Curtin School of Medical Research building on the ANU campus. All our staff and students are once again under one roof, carrying out their research in state of the art laboratories and facilities.
    [Show full text]
  • Understanding Genomics
    Predict Diagnose Treat Understanding genomics A comprehensive guide brought to you by Garvan. Contents What is genomics? 4 A short history of DNA 5 Genomics information for a lifetime 7 Conversations about genomics 11 How does genome sequencing work? 12 Can I have my genome sequenced? 13 Genomics research at Garvan 14 Garvan’s genomics research programs 18 Genomics research centres 20 Useful terms 22 Predict Diagnose Treat 2 3 Professor Chris Goodnow FAA FRS Executive Director, Garvan Institute of Medical Research The Bill and Patricia Ritchie Foundation Chair Dear Friend, I’m Professor Chris Goodnow, Executive Director of the Garvan Institute of Medical Research in Sydney. I wanted to introduce myself and thank you for your interest in understanding genomics. Genomics is the study of genes and other information encoded in an individual’s genome—the complete set of instructions in their DNA. Each person has different DNA, unique just to you. Every disease has a genetic component. Through genomics research, we can further understand what our genetic information – and our gene or genetic variations – mean for our health. Garvan scientists use genomics research to understand more about disease and determine how to best diagnose, treat and prevent it. I hope you find this brochure informative and useful and consider joining our family, pioneering the future of medical research. Yours sincerely, Chris We see a future where an individual’s DNA is used to better predict, diagnose and treat disease. It’s within reach. 2 3 What is genomics? Genomics is the study of your genome – all the information encoded in your DNA.
    [Show full text]
  • Curriculum Vitae
    Curriculum Vitae Name in Full: Shimon Sakaguchi Birth Date: January 19, 1951 Institutions Attended: Kyoto University Premedical Course 1970-1972 Kyoto University Medical School 1972-1976 Degrees Acquired: Doctor of Medicine (M.D.) 1976 Doctor of Philosophy (Ph.D.) 1983 Research and Professional Experiences: Resident, Department of Pathology, Kyoto University Medical School and Hospital 1976-1978 Visiting Investigator, Laboratory of Pathology Aichi Cancer Center Research Institute 1978-1981 Senior Research Fellow, Institute for Immunology Kyoto University Medical School 1981-1983 Joint Appointment at the Blood Transfusion Service, Kyoto University Hospital 1981-1983 Postdoctoral Fellow, Department of Immunology and Infectious Diseases, The Johns Hopkins Medical Institutions 1983-1985 Postdoctoral Fellow (Lucille P. Markey Scholar), Department of Biophysics The Johns Hopkins Medical Institutions 1986-1987 Visiting Scientist, Division of Immunology and Rheumatology, Stanford University Medical Center 1987-1989 Assistant Professor, Department of Immunology, Scripps Research Institute 1989-1991 Investigator, Science and Technology Agency of Japan 1992-1994 Head, Department of Immunopathology, Tokyo Metropolitan Institute of Gerontology 1994-1997 Chair and Professor, Department of Experimental Pathology, Institute for Frontier Medical Sciences, Kyoto University 1998-2011 Director, Institute for Frontier Medical Sciences, Kyoto University 2007-2011 Visiting Professor, Institute for Frontier Medical Sciences, Kyoto University 2011-present Professor, Department of Experimental Immunology, Immunology Frontier Research Center, Osaka University 2011-present Adjunct Professor of Oncology, Roswell Park Cancer Institute, USA 2012-present Vice-director, Immunology Frontier Research Center, Osaka University 2012 –present Distinguished Professor, Osaka University 2013-present President of Japanese Society of Immunologists 2016-present Awards and honors: Lucille P. Markey Scholar Award in Biomedical Science 1986 Mochida Science Award 2003 Cancer Research Institute’s William B.
    [Show full text]
  • Critical Roles of Chemokine Receptor CCR10 in Regulating Memory Iga
    Critical roles of chemokine receptor CCR10 in PNAS PLUS regulating memory IgA responses in intestines Shaomin Hu, KangKang Yang, Jie Yang, Ming Li, and Na Xiong1 Center for Molecular Immunology and Infectious Diseases and Department of Veterinary and Biomedical Sciences, Pennsylvania State University, University Park, PA 16802 Edited by Rino Rappuoli, Novartis Vaccines, Siena, Italy, and approved September 12, 2011 (received for review January 5, 2011) Chemokine receptor CCR10 is expressed by all intestinal IgA-pro- specificIgA+ plasma cells could be maintained in the intestine for ducing plasma cells and is suggested to play an important role in a long time in the absence of antigenic stimulation (half-life > 16 positioning these cells in the lamina propria for proper IgA pro- wk), suggesting that unique intrinsic properties of the IgA- duction to maintain intestinal homeostasis and protect against producing plasma cells and intestinal environments might collabo- infection. However, interfering with CCR10 or its ligand did not rate to maintain the prolonged IgA production. However, mainte- impair intestinal IgA production under homeostatic conditions or nance of the antigen-specific IgA-producing plasma cells is during infection, and the in vivo function of CCR10 in the intestinal significantly affected by continuous presence of commensal bacte- IgA response remains unknown. We found that an enhanced ria, which induce generation of new IgA-producing plasma cells generation of IgA+ cells in isolated lymphoid follicles of intestines that replace the existing antigen-specificIgA+ cells in the intestine. offset defective intestinal migration of IgA+ cells in CCR10-KO mice, Molecular factors involved in the long-term IgA maintenance are resulting in the apparently normal IgA production under homeo- largely unknown and it is also not well understood how IgA memory static conditions and in primary response to pathogen infection.
    [Show full text]
  • CX3CR1) Modulator, Attenuates Mucosal Inflammation and Reduces CX3CR11 Leukocyte Trafficking in Mice with Colitis
    1521-0111/92/5/502–509$25.00 https://doi.org/10.1124/mol.117.108381 MOLECULAR PHARMACOLOGY Mol Pharmacol 92:502–509, November 2017 Copyright ª 2017 by The American Society for Pharmacology and Experimental Therapeutics E6130, a Novel CX3C Chemokine Receptor 1 (CX3CR1) Modulator, Attenuates Mucosal Inflammation and Reduces CX3CR11 Leukocyte Trafficking in Mice with Colitis Hisashi Wakita, Tatsuya Yanagawa, Yoshikazu Kuboi, and Toshio Imai Eisai Co., Ltd., Tsukuba Research Laboratories, Ibaraki (H.W., T.Y., Y.K.) and KAN Research Institute Inc., Hyogo (T.I.), Japan Received February 1, 2017; accepted August 16, 2017 Downloaded from ABSTRACT The chemokine fractalkine (CX3C chemokine ligand 1; CX3CL1) (IC50 4.9 nM), most likely via E6130-induced down-regulation of and its receptor CX3CR1 are involved in the pathogenesis of CX3CR1 on the cell surface. E6130 had agonistic activity via several diseases, including inflammatory bowel diseases such as CX3CR1 with respect to guanosine 59-3-O-(thio)triphosphate Crohn’s disease and ulcerative colitis, rheumatoid arthritis, hepa- binding in CX3CR1-expressing Chinese hamster ovary K1 titis, myositis, multiple sclerosis, renal ischemia, and athero- (CHO-K1) membrane and had no antagonistic activity. Orally sclerosis. There are no orally available agents that modulate the administered E6130 ameliorated several inflammatory bowel molpharm.aspetjournals.org fractalkine/CX3CR1 axis. [(3S,4R)-1-[2-Chloro-6-(trifluoromethyl) disease–related parameters in a murine CD41CD45RBhigh benzyl]-3-{[1-(cyclohex-1-en-1-ylmethyl)piperidin-4-yl]carbamoyl}- T-cell-transfer colitis model and a murine oxazolone-induced 4-methylpyrrolidin-3-yl]acetic acid (2S)-hydroxy(phenyl)acetate colitis model.
    [Show full text]
  • Annual Report (March 2010-February 2011)
    EMBL Australia Annual Report [March 2010 – February 2011] 2 EMBL AUSTRALIA ANNUAL REPORT 2009–10 Contents Chairman’s report 2 Scientific Head’s report 3 About EMBL Australia 4 The European Molecular Biology Laboratory 4 2010 Highlights 5 2011 Outlook 6 Key activities 7 Launch by Minister Carr 7 Appointment of Scientific Head 8 EBI Mirror Facility and the National Bioinformatics Network 8 EBI Mirror at The University of Queensland 8 EMBL Australia Bioinformatics Network 9 International PhD Program 9 Partner Laboratory Network 9 Appointment of Edwina McGlinn 10 Appointment of Nicolas Platcha 11 Faculty Development Program 11 Sponsorship of BioInfoSummer 11 Governance 12 EMBL Australia participant expansion 12 Council 12 Appointment of new members 12 Council Members 12 Meetings 12 Planning and Finance Committee 13 Members 13 Meetings 13 Bioinformatics Committee 13 Members 13 Meetings 13 Staff 14 Australian visitors to EMBL 2010 15 Visitors to EMBL Australia 15 Financial report 16 Documents and Media releases 18 Funding & Stakeholders 20 Participants 20 Funding and in-kind support 20 Contact details inside back cover 1 Chairman’s report 2010 was a seminal year in the EMBL Australia initiative. Our official launch by Minister Carr in March coincided with the announcement of several key developments. These developments included the appointments of our Scientific Head and first Partner Laboratory Group Leaders, along with the announcement of a second node and associated national network for bioinformaticians. EMBL Australia’s participation is set to expand, with invitations accepted by the remaining Go8 universities to join EMBL Australia. This will extend direct involvement to a wider group of research institutions and expand the potential reach of EMBL Australia programs.
    [Show full text]
  • June 06.Indd
    NEWSLETTER Australasian Society for Immunology Incorporated PP 341403100035 ISSN 1442-8725 June 2006 Overview of the JCSMR Immunogenomics Laboratory 2006 Gerard Hoyne Overview they were able to reveal that the autoimmune but Dr Horikawa, a postodoctoral fellow in The Immunogenomics Laboratory at the regulator gene AIRE, which is expressed by the lab, has made the remarkable fi nding that John Curtin School of Medical Research in a subset of thymic epithelial cells, plays a the exact opposite is the case. The memory Canberra comprises four research groups critical role in establishing T cell tolerance B cell receptor is less active at inducing a working in concert to develop an integrated to self antigens in the thymus. In addition, subset of genes, and in this case less signal understanding of how our immune system is Adrian also identifi ed that defective signals means more antibody formation. controlled at the cellular and molecular level to cell death genes account for the inherited by circuits that are specifi ed in our genome resistance of T lymphocytes to clonal deletion Carola Vinuesa heads the Humoral sequence. Each of the groups focuses on in the thymus of NOD mice. Upon infection memory and Autoimmunity Group. a different element of a fundamental set with a virus or bacteria, B lymphocytes with Her group is investigating the cellular and of immune system decisions made at the the right antigen receptors to neutralize molecular events that regulate production level of individual immune system cells: infection are stimulated to switch the isotype and selection versus elimination of memory either to fi ght or to disarm.
    [Show full text]
  • CCBP2 293 Cell Lysate Storage: Store at -80°C
    From Biology to Discovery™ CCBP2 293 Cell Lysate Storage: Store at -80°C. Minimize freeze-thaw cycles. After addition of 2X SDS Loading Buffer, the lysates can be stored Subcategory: Cell Lysate at -20°C. Product is guaranteed 6 months from the date of Cat. No.: 400521 shipment. Unit: 0.1 mg For research use only, not for diagnostic or therapeutic Description: procedures. Antigen standard for chemokine binding protein 2 (CCBP2) is a lysate prepared from HEK293T cells transiently transfected with a TrueORF gene-carrying pCMV plasmid (OriGene Technologies, Inc.) and then lysed in RIPA Buffer. Protein concentration was determined using a colorimetric assay. The antigen control carries a C-terminal Myc/DDK tag for detection. Applications: ELISA, WB, IP Format: This product includes 3 vials: 1 vial of gene-specific cell lysate, 1 vial of control vector cell lysate, and 1 vial of loading buffer. Each lysate vial contains 0.1 mg lysate in 0.1 ml (1 mg/ml) of RIPA Buffer (50 mM Tris-HCl pH7.5, 250 mM NaCl, 5 mM EDTA, 50 mM NaF, 1% NP40). The loading buffer vial contains 0.5 ml 2X SDS Loading Buffer (125 mM Tris-Cl, pH6.8, 10% glycerol, 4% SDS, 0.002% Bromophenol blue, 5% beta-mercaptoethanol). Alternate Names: CC-chemokine-binding receptor JAB61; chemokine (C-C) receptor 9; chemokine (C-C motif) receptor 9; chemokine receptor D6; chemokine receptor CCR-9; C-C chemokine receptor D6; chemokine receptor CCR-10; chemokine-binding protein D6; CCBP2; CCR10; CCR9; CMKBR9; D6; hD6; MGC126678; MGC138250 Accession No.: NP_001287 Application Notes: WB: Mix equal volume of lysates with 2X SDS Loading Buffer.
    [Show full text]
  • Ccl27/Ccl2 Ccl28
    UNIVERSITY OF CALIFORNIA, SAN DIEGO Structural and Functional Analysis of the Chemokine CCL27 and the Expression and Purification of Silent Chemokine Receptors D6 and DARC A dissertation submitted in partial satisfaction of the requirements for the degree of Doctor of Philosophy in Chemistry and Biochemistry by Ariane L. Jansma Committee in charge: Professor Tracy M. Handel, Chair Professor Patricia Jennings, Co-Chair Professor William Gerwick Professor Susan Taylor Asst. Professor Faik A. Tezcan 2009 This Dissertation of Ariane L. Jansma is approved, and it is acceptable in quality and form for publication on microfilm and electronically: ________________________________________________________ ________________________________________________________ ________________________________________________________ ________________________________________________________ Co-Chair ________________________________________________________ Chair iv TABLE OF CONTENTS Signature Page ................................................................................................................ iii Table of Contents............................................................................................................. iv List of Figures.................................................................................................................... x List of Tables...................................................................................................................xiii List of Abbreviations........................................................................................................xiv
    [Show full text]
  • THE JOHN CURTIN SCHOOL of MEDICAL RESEARCH Annual Review 2013
    THE JOHN CURTIN SCHOOL OF MEDICAL RESEARCH Annual Review 2013 ANU College of Medicine, Biology & Environment CONTENTS Annual Review 2013 The John Curtin School of Medical Research From the Director 3 Staff and student lists 87 Department of Genome Biology 88 Organisation Chart 4 Department of Immunology 90 Committees 5 Eccles Institute of Neuroscience 92 Department of Molecular Bioscience 94 Community 7 Department of Translational Medicine 96 Department of Pathogens and Immunity 96 Centenary of Canberra 2013 Australian Phenomics Facility 97 14th Frank and Bobbie Fenner Conference 8 School Administration 98 The John Curtin Medical Research Foundation Dinner 9 School Services 98 David Curtis Reading Room 10 The ACRF Biomolecular Resource Facility Open Day 2013 11 and Genome Discovery Unit 99 Community Activities 12 Students 100 Research in Review 2013 15 Publications, presentations and Eccles Institute of Neuroscience 16 community outreach 103 Department of Genome Biology 30 Publications 104 Department of Immunology 38 Staff Presentations 110 Department of Pathogens and Immunity 48 Student Presentations 117 Department of Molecular Bioscience 52 Community Outreach 121 Department of Translational Medicine 58 Australian Phenomics Facility 60 Support to JCSMR 131 The Imaging and Cytometry Facility 62 Grants 132 The ACRF Biomolecular Resource Facility Financial Overview 136 and Genome Discovery Unit 63 Donors 137 Staff and student achievements 65 Sponsors 138 Graduates 66 Prizes and Awards 67 Visitors and collaborations 71 Visitors 72 Collaborations 74 Annual Review 2013 1 2 The John Curtin School of Medical Research FROM THE DIRECTOR Following the opening of Stage 3 of our new building in 2012, JCSMR staff and students have enjoyed the opportunities provided by the new spaces, including the laboratories, and meeting rooms such as the Science Forum.
    [Show full text]